The effect of acetylsalicylic acid on vasopressin, serum insulin levels, insulin resistance, and biochemical parameters in rats induced with experimental diabetes type 2

Background/aim: Acetylsalicylic acid (ASA) treatment in diabetic patients is very important owing to the increasing hyperactivity of thrombocytes and atherosclerosis. In several investigations, it was reported that diabetes caused increased coronary artery disease, cerebrovascular disease, and death. In this study, we aimed to investigate the effect of ASA on osmoregulation, glycemic control, and some biochemical parameters in rats induced with experimental diabetes type 2. Materials and methods: Twenty-four rats were randomly divided in four groups: control (I), ASA control (II), diabetic (III), and ASA diabetic (IV). Diabetes was induced by streptozotocin treatment (30 mg/kg, twice, intraperitoneal injection) in obese rats. ASA (150 mg/kg body weight, orally) was administered for 5 weeks in the ASA control and ASA diabetic groups. Serum electrolytes, creatinine, albumin, and total protein levels were analyzed with an autoanalyzer. Arginine vasopressin (AVP) and insulin were analyzed by ELISA techniques. Results: At the end of the study ASA treatments had decreased the fasting blood glucose levels but had interestingly increased the serum AVP levels in diabetics rats. Conclusion: AVP levels were increased 2-fold by ASA treatment in diabetic rats. For the first time in this study, the hypoglycemic effect of ASA was attributed to an increase in blood volume by AVP levels. This explanation may be a new approach to the literature on this topic.

PDF

___

1. Kahn CR, Weir GC, King GL, Jacobson AM, Moses AC, Smith RJ. Joslins Diabetes Mellitus. 14th ed. Boston, MA, USA: Lippincott Williams & Wilkins; 2004.
2. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999; 281: 2005-2012.
3. American Diabetes Association: standards of medical care in diabetes. Diabetes Care 2014; 37-1: 14-80.
4. The Emerging Risk Factors Collaboration. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011; 364: 829-841.
5. Singer DE, Nathan DM, Anderson KM, Wilson PW, Evans JC. Association of HbA1c with prevalent cardiovascular disease in the original cohort of the Framingham Heart Study. Diabetes 1992; 41: 202-208.
6. Ross R. Atherosclerosis an inflammatory disease. N Engl J Med 1999; 340: 115-126.
7. Hayden RM, Tyagi SC. Is type 2 diabetes mellitus a vascular disease (atheroscleropathy) with hyperglycemia a late manifestation? The role of NOS, NO, and redox stress. Cardiovasc Diabetol 2003; 2: 1-10.
8. Muhlestein JB. Effect of antiplatelet therapy on inflammatory markers in atherothrombotic patients. Thromb Haemost 2010; 103: 71-82.
9. Jain S, Saraf S. Type 2 diabetes mellitusIts global prevalence and therapeutic strategies. Diabetes Metab Syndr Clin Res Rev 2010; 4: 48-56.
10. Kantarcı G, Demiran G. New options for old diseases: aquaretics (vasopressin receptor antagonists). Turk Neph Dial Transpl 2011; 20: 14-18.
11. Reed MJ, Meszaros K, Entes LJ, Claypool MD, Pinkett JG, Gadbois TM, Reaven GM. A new rat model of type 2 diabetes: the fat-fed, streptozotocin-treated rat. Metabolism 2000; 49: 1390-1394.
12. Srinivasan K, Viswanad B, Asrat L, Kaul CL, Ramarao P. Combination of high-fat diet-fed and low-dose streptozotocintreated rat: a model for type 2 diabetes and pharmacological screening. Pharmacol Res 2005; 52: 313-320.
13. Zhou J, Zhou S, Tang J, Zhang K, Guang L, Huang Y, Xu Y, Ying Y, Zhang L, Li D. Protective effect of berberine on beta cells in streptozotocin- and high-carbohydrate/high-fat diet-induced diabetic rats. Eur J Pharmacol 2009; 606: 262-268.
14. Furnes MW, Zhao CM, Chen D. Development of obesity is associated with increased calories per meal rather than per day. A study of high-fat diet-induced obesity in young rats. Obes Surg 2009; 19: 1430-1438.
15. Fam BC, Morris MJ, Hansen MJ, Kebede M, Andrikopoulos S, Proietto J, Thorburn AW. Modulation of central leptin sensitivity and energy balance in a rat model of diet-induced obesity. Diabetes Obes Metab 2007; 9: 840-852.
16. Zhang M, Lv MY, Li J, Xu ZG, Chen L. The characterization of high-fat diet and multiple low-dose streptozotocin induced type 2 diabetes rat model. Exp Diabetes Res 2008; 2008: 1-9.
17. Woods SC, Seeley RJ, Rushing PA, DAlessio, Tso P. A controlled high-fat diet induces an obese syndrome in rats. J Nutr 2003; 133: 1081-1087.
18. Durham HA, Truett GE. Development of insulin resistance and hyperphagia in Zucker fatty rats. Am J Physiol Regul Integr Comp Physiol 2006; 290: 652-658.
19. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
20. Fleischman A, Shoelson SE, Bernier R, Goldfine AB. Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care 2008; 31: 289-294.
21. Goldfine AB, Fonseca V, Jablonski KA, Pyle L, Staten MA, Shoelson SE. Tinsal-T2d (Targeting Inflammation Using Salsalate in Type 2 Diabetes) study Team (2010). The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. Ann Intern Med 2010; 152: 346-357.
22. Yibchok-Anun S, Abu-Basha EA, Yao CY, Panichkriangkrai W, Hsu WH. The role of arginine vasopressin in diabetes-associated increase in glucagon secretion. Regul Pept 2004; 122: 157-162.
23. Dheen ST, Tay SS, Wong WC. Arginine vasopressin- and oxytocinlike immunoreactive neurons in the hypothalamic paraventricular and supraoptic nuclei of streptozotocin-induced diabetic rats. Arch Histol Cytol 1994; 57: 461-472.
24. Bankir L, Bardoux P, Ahloulay M. Vasopressin and diabetes mellitus. Nephron 1991; 87: 8-18.
25. Sands JM, Bichet DG. American College of Physicians; American Physiological Society. Nephrogenic diabetes insipidus. Ann Intern Med 2006; 144: 186-194.
26. Bell TN. Diabetes insipidus. Crit Care Nurs Clin North Am 1999; 6: 675-685.
27. Metz SA. Anti-inflammatory agents as inhibitors of prostaglandin synthesis in man. Med Clin North Am 1981; 65: 713-757.